As cancers grow and potentially spread to new areas of the body, tests like liquid biopsies have become standard practice for some cancers, particularly those with drugs that treat the DNA mutation. Liquid biopsies are analyses of the amount of DNA present and whether any potential mutations exist, and this test is crucial for helping providers choose a treatment method. Zachery Reichert, M.D., Ph.D., a clinical associate professor, discusses the impact such tests can have and the development of tumor fractioning to aid in the cause.
